Management of functional pulmonary atresia with isoproterenol in a neonate with Ebstein's anomaly.
Ebstein's anomaly is a rare congenital cardiac anomaly showing significant clinical manifestations with a high mortality rate in the neonatal period. The prognosis of the patient is essentially determined by the severity in morphological changes, however, high pulmonary vascular resistance in the neonatal period may aggravate tricuspid regurgitation and lead to functional pulmonary atresia. We describe a critically ill neonate with morphologically mild Ebstein's anomaly who was successfully managed with intensive care including isoproterenol administration for functional pulmonary atresia. Isoproterenol is a potent pulmonary vasodilator with inotropic and chronotropic effects, and seemed to decrease the pulmonary vascular resistance allowing increased antegrade blood flow to the pulmonary artery and improved cardiac output. If tachycardia is not present, isoproterenol administration is recommended in critically ill neonates with anatomically mild Ebstein's anomaly and no associated cardiac defects.
Suzuki
H
H
Department of Pediatrics, Yamagata University School of Medicine, Japan.
Nakasato
M
M
Sato
S
S
Komatsu
H
H
Hayasaka
K
K
D004437:Ebstein Anomaly / Q000150:complications* / Q000000981:diagnostic imaging; D015150:Echocardiography, Doppler; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007545:Isoproterenol / Q000627:therapeutic use*; D018633:Pulmonary Atresia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011859:Radiography; D014262:Tricuspid Valve Insufficiency / Q000150:complications / Q000000981:diagnostic imaging; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D007545:Isoproterenol